To address drug shortages with neuromuscular blocking agents used in the management of critically ill patients with COVID-19, FDA has allowed vials of rocuronium and vecuronium to be temporarily manufactured without the usual vial cap warnings.
Maria G. Tanzi, PharmD
During the current pandemic, salicylate intoxication is unlikely to be at the top of many clinicians’ differential diagnosis list.
Joey Sweeney, PharmD, BCPS
Trending Topics in Health-System Pharmacy
In May, FDA approved dapagliflozin to treat patients with New York Heart Association (NYHA) class II–IV heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization.
Superinfections—infections that occur alongside another infection—are often present in patients who have died from COVID-19.